EEDQ reduces the striatal neurotensin mRNA response to haloperidol

Peptides

Volumn 18, Issue 4, 1997, Pages 527-535

  Adams, Monique R ^a   Dobie, Dorcas J ^b   Merchant, Kalpana M ^c   Unis, Alan ^a   Dorsa, Daniel M ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c PFIZER INC   (United States)

Author keywords

Antipsychotic; Dopamine; Dorsolateral striatum; Drugs Haloperidol; EEDQ; Neurotensin neuromedin N

Indexed keywords

2 ETHOXY 1(2H) QUINOLINECARBOXYLIC ACID ETHYL ESTER; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; MESSENGER RNA; NEUROLEPTIC AGENT; NEUROMEDIN N; NEUROTENSIN; SIGMA OPIATE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; GENE EXPRESSION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; RAT; RECEPTOR DENSITY; SCHIZOPHRENIA;

ANIMALIA;

EID: 0030973303     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(97)87957-0     Document Type: Article

References (45)

1. Adler, C. H.; Meller, E.; Goldstein, M. Recovery of alpha 2-adrenoceptor binding and function after irreversible inactivation by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ). Eur. J. Pharmacol. 116:175-178; 1985.
2. Augood, S. J.; Kiyama, H.; Faull, R. L.; Emson, P. C. Differential effects of acute dopaminergic Dl and D2 receptor antagonists on proneurotensin mRNA expression in rat striatum. Brain Res. Mol. Brain Res. 9:341-346; 1991.
3. Battaglia, G.; Norman, A. B.; Creese, I. Differential serotonin2 receptor recovery in mature and senescent rat brain after irreversible receptor modification: Effect of chronic reserpine treatment. J. Pharmacol. Exp Ther. 243:69-75; 1987.
4. Bissette, G.; Nemeroff, C. B.; Loosen, P. T.; Prange, A. J., Jr.; Lipton, M. A. Hypothermia and intolerance to cold induced by intracisternal administration of the hypothalamic peptide neurotensin. Nature. 262:607-609; 1976.
5. Bouthenet, M. L.; Souil, E.; Martres, M. P.; Sokoloff, P.; Giros, B.; Schwartz, J. C. Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: Comparison with dopamine D2 receptor mRNA. Brain Res. 564:203-219; 1991.
6. Carraway, R.; Leeman, S. E. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J. Biol. Chem. 248:6854-6861; 1973.
7. Castel, M. N.; Morino, P.; Hokfelt, T. Modulation of the neurotensin striato-nigral pathway by Dl receptors. Neuroreport 5:281-284; 1993.
8. Creese, I.; Burt, D. R.; Snyder, S. H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481-483; 1976.
9. Deutch, A. Y.; Cameron, D. S. Pharmacological characterization of dopamine systems in the nucleus accumbens core and shell. Neuroscience 46:49-56; 1992.
10. Eggerman, K. W.; Zahm, D. S. Numbers of neurotensin-immunoreactive neurons selectively increased in rat ventral striatum following acute haloperidol administration. Neuropeptides 11:125-132; 1988.
11. Ervin, G. N.; Birkemo, L. S.; Nemeroff, C. B.; Prange, A. J., Jr. Neurotensin blocks certain amphetamine-induced behaviours. Nature 291:73-76; 1981.
12. Frey, P.; Fuxe, K.; Eneroth, P.; Agnati, L. F. Effects of acute and long-term treatments with neuroleptics on regional telencephalic neurotensin levels in the male rat. Neurochem Int. 8:429-434; 1986.
13. Gerlach, J.; Koppelhus, P.; Heiweg, E.; Monrad, A. Clozapine and haloperidol in a single-blind cross-over trial: Therapeutic and biochemical aspects in the treatment of schizophrenia. Acta. Psychiatr. Scand. 50:410-414; 1975.
14. Govoni, S.; Hong, J. S.; Yang, H. Y.; Costa, E. Increase of neurotensin content elicited by neuroleptics in nucleus accumbens. J. Pharmacol. Exp Ther. 215:413-417; 1980.
15. Hamblin, M. W.; Creese, I. Behavioral and radioligand binding evidence for irreversible dopamine receptor blockade by N-ethoxycarbonyl-2-ethoxy-l,2-dihydroquinoline. Life Sci. 32:2247-2255; 1983.
16. Heimer, L.; Zahm, D. S.; Churchill, L.; Kalivas, P. W.; Wohltmann, C. Specificity in the projection patterns of accumbal core and shell in the rat. Neuroscience. 41:89-125; 1991.
17. Hess, E. J.; Battaglia, G.; Norman, A. B.; Creese, I. Differential modification of striatal Dl dopamine receptors and effector moieties by N-ethoxycarbonyl-2-ethoxy-l,2-dihydroquinoline in vivo and in vitro. Mol Pharmacol. 31:50-57; 1987.
18. Hillefors Berglund, M.; Von Euler, G. Pharmacology of dopamine D3 receptors in the islands of Calleja of the rat using quantitative receptor autoradiography. Eur. J. Pharmacol. 261:179-183; 1994.
19. Iversen, L. L.; Iversen, S. D.; Bloom, F.; Douglas, C.; Brown, M.; Vale, W. Calcium-dependent release of somatostatin and neurotensin from rat brain in vitro. Nature. 273:161-163; 1978.
20. Jaen, J. C.; Caprathe, B. W.; Pugsley, T. A.; Wise, L. D.; Akunne, H. Evaluation of the effects of the enantiomers of reduced haloperidol, azaperol, and related 4-amino-1-arylbutanols on dopamine and sigma receptors. J. Med. Chem. 36:3929-3936; 1993.
21. Kalivas, P. W.; Burgess, S. K.; Nemeroff, C. B.; Prange, A. J., Jr. Behavioral and neurochemical effects of neurotensin microinjection into the ventral tegmental area of the rat. Neuroscience 8:495-505; 1983.
22. Kitabgi, P.; Carraway, R.; Van Rietschoten, J.; Granier, C.; Morgat, J. L.; Menez, A.; Leeman, S.; Freychet, P. Neurotensin: Specific binding to synaptic membranes from rat brain. Proc. Natl. Acad. Sci. U S A. 74:1846-1850; 1977.
23. Letter, A. A.; Matsuda, L. A.; Merchant, K. M.; Gibb, J. W.; Hanson, G. R. Characterization of dopaminergic influence on striatal-nigral neurotensin systems. Brain Res. 422:200-203; 1987.
24. 3H] quinpirole: Identification of a discrete population of putative D3 receptors. Synapse 14:90-95; 1993.
25. Levant, B.; Merchant, K. M.; Dorsa, D. M.; Nemeroff, C. B. BMY 14802, a potential antipsychotic drug, increases expression of proneurotensin mRNA in the rat striatum. Brain Res. Mol. Brain Res. 12:279-284; 1992.
26. Meller, E.; Bohmaker, K.; Goldstein, M.; Friedhoff, A. J. Inactivation of Dl and D2 dopamine receptors by N-ethoxycarbonyl-2-ethoxy-l,2-dihydroquinoline in vivo: Selective protection by neuroleptics. J. Pharmacol. Exp. Ther. 233:656-662; 1985.
27. Merchant, K. M. c-fos antisense oligonucleotide specifically attenuates haloperidol-induced increases in neurotensin/neuromedin N mRNA expression in rat dorsal striatum. Mol. Cell. Neurosci. 5:336-344; 1994.
28. Merchant, K. M.; Dobie, D. J.; Dorsa, D. M. Expression of the proneurotensin gene in the rat brain and its regulation by antipsychotic drugs. Ann. NY Acad. Sci. 668:54-69; 1992.
29. Merchant, K. M.; Dobner, P. R.; Dorsa, D. M. Differential effects of haloperidol and clozapine on neurotensin gene transcription in rat neostriatum. J. Neurosci. 12:652-663; 1992.
30. Merchant, K. M.; Dorsa, D. M. Differential induction of neurotensin and c-fos gene expression by typical vs. atypical antipsychotics. Proc. Natl. Acad. Sci. USA. 90:3447-3451; 1993.
31. Merchant, K. M.; Miller, M. A.; Ashleigh, E. A.; Dorsa, D. M. Haloperidol rapidly increases the number of neurotensin mRNA-expressing neurons in neostriatum of the rat brain. Brain Res. 540:311-314; 1991.
32. Neisewander, J. L.; O'Dell, L. E.; Redmond, J. C. Localization of dopamine receptor subtypes occupied by intra-accumbens antagonists that reverse cocaine-induced locomotion. Brain Res. 671:201-212; 1995.
33. Nemeroff, C. B. Neurotensin: Perchance an endogenous neuroleptic? Biol. Psychiatry. 15:283-302; 1980.
34. Norman, A. B.; Battaglia, G.; Creese, I. Differential recovery rates of rat D2 dopamine receptors as a function of aging and chronic reserpine treatment following irreversible modification:A key to receptor regulatory mechanisms. J.. Neurosci. 7:1484-1491; 1987.
35. Pakkenberg, B. Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics. Arch. Gen. Psychiatry. 47:1023-1028; 1990.
36. Paxinos, G.; Watson, C. The rat brain in stereotaxic coordinates. Sydney, Australia: Academic; 1986.
37. Pritchett, D. B.; Bach, A. W.; Wozny, M.; Taleb, O.; Dal Toso, R.; Shih, J. C.; Seeburg, P. H. Structure and functional expression of cloned rat serotonin 5HT-2 receptor. Embo. J. 7:4135-4140; 1988.
38. Seeman, P.; Lee, T.; Chau Wong, M.; Wong, K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261:717-719; 1976.
39. Uhl, G. R. Distribution of neurotensin and its receptor in the central nervous system. Ann. NY Acad. Sci. 400:132-149; 1982.
40. Uhl, G. R.; Snyder, S. H. Regional and subcellular distributions of brain neurotensin. Life. Sci. 19:1827-1832; 1976.
41. 3H] 1,3-di-o-tolylguanidine (DTG) binding sites in guinea pig brain: A comparative study. Brain Res. 581:33-38; 1992.
42. Walker, J. M.; Bowen, W. D.; Walker, F. O.; Matsumoto, R. R.; De Costa, B.; Rice, K. C. Sigma receptors: Biology and function. Pharmacol. Rev. 42:355-402; 1990.
43. Widerlov, E.; Lindstrom, L. H.; Besev, G.; Manberg, P. J.; Nemeroff, C. B.; Breese, G. R.; Kizer, J. S.; Prange, A. J., Jr. Subnormal CSF levels of neurotensin in a subgroup of schizophrenic patients: Normalization after neuroleptic treatment. Am. J. Psychiatry. 139:1122-1126; 1982.
44. Young, W. S. d.; Kuhar, M. J. Neurotensin receptor localization by light microscopic autoradiography in rat brain. Brain Res. 206:273-285; 1981.
45. Zahm, D. S. The ventral striatopallidal parts of the basal ganglia in the rat-II. Compartmentation of ventral pallidal efferents. Neuroscience 30:33-50; 1989.